Percutaneous Ultrasound-Guided Radiofrequency Thermal Ablation for Treatment of Uterine Fibroids

Raúl García Marcos, Javier Monleón, Alicia Martínez-Varea, Fernando Gómez, Guillermina Montoliú, Jose J. Martínez, Luis Martí-Bonmatí, Antonio Pellicer

Department Obstetrics and Gynecology, La Fe University Hospital, Valencia, Spain.
Department of Radiology, Hospital Clinic, Barcelona, Spain.
Department of Radiology, La Fe University Hospital, Valencia, Spain.

DOI: 10.4236/ojog.2014.412100                

Abstract

Purpose: To assess the safety, efficacy and effectiveness of percutaneous radiofrequency (RF) thermal ablation to reduce symptoms of uterine fibroids. Materials and Methods: 17 premenopausal women with symptomatic uterine fibroids despite conventional medical treatment were included. The assessment of symptoms and characteristics of fibroids by vaginal ultrasound, magnetic resonance imaging (MRI) and contrast enhanced ultrasound (CEUS) was performed before starting treatment and 6 months after the procedure. Successful treatment was clinically considered if patients reported a reduction in symptoms 6 months after RF myolysis. Successful treatment was also considered if the necrosis of the fibroid was greater than 50%, 6 months after treatment. Results: The baseline score on visual analogue scale (VAS) for dysmenorrhea and intermenstrual pain was 5.76 ± 3.31 and 3.0 ± 3.4, respectively. According to a score of 0 - 3, baseline bleeding during menstruation was 2.29 ± 0.92. Six months after RF myolysis, the VAS for dysmenorrhea was 2.75 ± 3.32 (p = 0.004), whereas for intermenstrual pain it was 1.38 ± 2.56 (p = 0.02). Menstrual bleeding was reduced to 1.13 ± 0.89 (p = 0.005). Clinical success of the treatment was evident in 11 (64.7%) of the 17 patients with a 95% CI [38.6%, 84.7%]. Fourteen patients underwent MRI monitoring 6 months post-myolysis. Compared to baseline fibroid volume, ultrasound and MRI volume were 57.38% and 79.66% six months after surgery, respectively. A total of 13 patients (92.86%) had radiological success from the treatment (95% CI [64.2%, 99.6%]). Conclusion: Since percutaneous RF myolysis reduces volume and symptoms of uterine fibroids, it may be considered as a valid treatment for symptomatic fibroids.

Keywords

Percutaneous Radiofrequency Thermal Ablation, Myolysis, Uterine Fibroids

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Kim, C.H., Kim, S.R., Lee, H.A., Kim, S.H., Chae, H.D. and Kang, B.M. (2011) Transvaginal Ultrasound-Guided Radiofrequency Myolysis for Uterine Myomas. Human Reproduction, 26, 559-563. http://dx.doi.org/10.1093/humrep/deq366
[2]	Bulun, S.E. (2013) Uterine Fibroids. New England Journal of Medicine, 369, 1344-1355. http://dx.doi.org/10.1056/NEJMra1209993
[3]	Lumsden, M.A. (2002) Embolization versus Myomectomy versus Hysterectomy: Which Is Best, When? Human Reproduction, 17, 253-259. http://dx.doi.org/10.1093/humrep/17.2.253
[4]	Jones, S., O’Donovan, P. and Toub, D. (2012) Radiofrequency Ablation for Treatment of Symptomatic Uterine Fibroids. Obstetrics and Gynecology International, 2012, Article ID: 194839. http://dx.doi.org/10.1155/2012/194839
[5]	Carrafiello, G., Recaldini, C., Fontana, F., et al. (2010) Ultrasound-Guided Radiofrequency Thermal Ablation of Uterine Fibroids: Medium-Term Follow-Up. CardioVascular and Interventional Radiology, 33, 113-119. http://dx.doi.org/10.1007/s00270-009-9707-3
[6]	Evans, P. and Brunsell, S. (2007) Uterine Fibroid Tumors: Diagnosis and Treatment. American Family Physician, 75, 1503-1508.
[7]	Dueholm, M., Lundorf, E., Hansen, E.S., Ledertoug, S. and Olesen, F. (2002) Accuracy of Magnetic Resonance Imaging and Transvaginal Ultrasonography in the Diagnosis, Mapping, and Measurement of Uterine Myomas. American Journal of Obstetrics & Gynecology, 186, 409-415. http://dx.doi.org/10.1067/mob.[phone]
[8]	Recaldini, C., Carrafiello, G., Laganà, D., et al. (2007) Percutaneous Sonographically Guided Radiofrequency Ablation of Medium-Sized Fibroids: Feasibility Study. American Journal of Roentgenology, 189, 1303-1306. http://dx.doi.org/10.2214/AJR.07.2184
[9]	Kroon, B., Johnson, N., Chapman, M., Yazdani, A. and Hart, R. (2011) Australasian CREI Consensus Expert Panel on Trial Evidence (ACCEPT) Group. Fibroids in Infertility—Consensus Statement from ACCEPT (Australasian CREI Consensus Expert Panel on Trial Evidence). Australian and New Zealand Journal of Obstetrics and Gynaecology, 51, 289-295. http://dx.doi.org/10.1111/j.1479-828X.2011.01300.x
[10]	Goldfarb, H.A. (2008) Myolysis Revisited. Journal of the Society of Laparoendoscopic Surgeons, 12, 426-430.
[11]	Subramaniam, R., Vijayananthan, A., Omar, S., Nawawi, O. and Abdullah, B. (2010) Uterine Artery Embolisation for Symptomatic Fibroids: The University of Malaya Medical Centre Experience. The Biomedical Imaging and Intervention Journal, 6, e27. http://dx.doi.org/10.2349/biij.6.3.e27
[12]	Donnez, J., Tomaszewski, J., Vázquez, F., et al. (2012) Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. The New England Journal of Medicine, 366, 421-432. http://dx.doi.org/10.1056/NEJMoa1103180
[13]	Donnez, J., Squifflet, J., Polet, R. and Nisolle, M. (2000) Laparoscopic Myolysis. Human Reproduction Update, 6, 609-613. http://dx.doi.org/10.1093/humupd/6.6.609
[14]	Garza Leal, J.G., Hernandez Leon, I., Castillo Saenz, L. and Lee, B.B. (2011) Laparoscopic Ultrasound-Guided Radiofrequency Volumetric Thermal Ablation of Symptomatic Uterine Leiomyomas: Feasibility Study Using the Halt 2000 Ablation System. Journal of Minimally Invasive Gynecology, 18, 364-371. http://dx.doi.org/10.1016/j.jmig.2011.02.006
[15]	Ghezzi, F., Cromi, A., Bergamini, V., Scarperi, S., Bolis, P. and Franchi, M. (2007) Midterm Outcome of Radiofrequency Thermal Ablation for Symptomatic Uterine Myomas. Surgical Endoscopy, 21, 2081-2085. http://dx.doi.org/10.1007/s00464-007-9307-8
[16]	Bergamini, V., Ghezzi, F., Cromi, A., et al. (2005) Laparoscopic Radiofrequency Thermal Ablation: A New Approach to Symptomatic Uterine Myomas. American Journal of Obstetrics Gynecology, 192, 768-773. http://dx.doi.org/10.1016/j.ajog.2004.10.591
[17]	Myers, E.R., Barber, M.D., Gustilo-Ashby, T., Couchman, G., Matchar, D.B. and McCrory, D.C. (2002) Management of Uterine Leiomyomata: What Do We Really Know? Obstetrics Gynecology, 100, 8-17. http://dx.doi.org/10.1016/S0029-7844(02)02019-7
[18]	Spies, J.B., Bruno, J., Czeyda-Pommersheim, F., Magee, S.T., Ascher, S.A. and Jha, R.C. (2005) Long-Term Outcome of Uterine Artery Embolization of Leiomyomata. Obstetrics Gynecology, 106, 933-939. http://dx.doi.org/10.1097/01.AOG.0000182582.64088.84
[19]	Yamashita, Y., Torashima, M., Takahashi, M., et al. (1993) Hyperintense Uterine Leiomyoma at T2-Weighted MR Imaging: Differentiation with Dynamic Enhanced MR Imaging and Clinical Implications. Radiology, 189, 721-725. http://dx.doi.org/10.1148/radiology.189.3.8234695
[20]	Harman, M., Zeteroglu, S., Arslan, H., Sengül, M. and Etlik, O. (2006) Predictive Value of Magnetic Resonance Imaging Signal and Contrast-Enhancement Characteristics on Post-Embolization Volume Reduction of Uterine Fibroids. Acta Radiologica, 47, 427-435. http://dx.doi.org/10.1080/02841850600557117